drugset
drugset / Trial / NCT04931147

A 3-part Study to Evaluate Safety, Tolerability, Food Effect and Drug-drug Interactions of RXC007 in Healthy Volunteers

NCT04931147 ↗

Phase 1 Completed 90 enrolled Redx Pharma Ltd Simbec Research · collab
RandomizedSequentialQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of RXC007.

Timeline

Start
2021-05-13
Primary completion
2023-03-08
Completion
2023-03-08

Drugs

EvaluationDrugModalityDoseRoute
Subject RXC007 Unknown 2 mg Oral

Indications

idiopathic pulmonary fibrosis kidney disorder metabolic dysfunction-associated steatohepatitis